^
Association details:
| Biomarker: | EGFR mutation + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) + HS-10241 (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced non-small cell lung cancer (NSCLC) harboring EGFR mutation.
Published date:
05/25/2023
Excerpt:
Of the 13 pts who had centrally confirmed EGFR mutation and MET-amplification (6 with GCN ≥10, and 7 with GCN ≥5 but < 10), 8 had PR (response rate 61.5%; 5 confirmed PR), and 4 had SD. Among the 8 pts achieving PR, there were 4 with GCN ≥10, and 4 with GCN ≥5 but < 10....HS-10241 in combination with almonertinib was well tolerated, and showed encouraging antitumor activity in treatment of advanced NSCLC with EGFR mutation and MET amplification following prior EGFR-TKI, whether MET GCN ≥10 or MET GCN ≥5 but < 10.
DOI:
10.1200/JCO.2023.41.16_suppl.e21134
Trial ID:
